SEC62 and melanoma: Additionally, various melanoma animal models can be used to prove if therapeutic approaches targeting Sec62, e.g., using thapsigargin and/or trifluoperazine, have the potential to (i) hamper de novo melanoma development or from precancerous lesions, (ii) suppress tumor growth, and (iii) inhibit lymphatic and hematogenous metastasis.